Citizens Financial Group reaffirmed its Market Outperform rating and $80 price target for CRISPR Therapeutics (NASDAQ: CRSP) on Tuesday, citing new gene therapy data and an expanded addressable market for the company’s pipeline.
The analyst reiterated its target, which implies roughly 40% upside from the stock’s closing price of $57.08 on Monday, ahead of a late-breaking presentation at the European Society of Cardiology Congress later this week. CRISPR Therapeutics is expected to unveil follow-up data for its ANGPTL3-targeting in vivo gene therapy, CTX310, at the event, which begins on August 28.
Citizens also highlighted an estimated 10-15% increase in CRISPR Therapeutics’ total addressable market following the U.S. Food and Drug Administration’s recent label expansion for Casgevy. The gene therapy, developed in partnership with Vertex Pharmaceuticals, now covers patients aged two years and older with sickle cell disease and transfusion-dependent beta-thalassemia. Vertex previously presented Casgevy data in children aged 5–11, supporting regulatory filings in multiple jurisdictions.
The analyst noted that CRISPR Therapeutics’ approach differs from traditional lipid-lowering therapies, which often target PCSK9 via oral medications, siRNA, or monoclonal antibodies. Instead, the company’s gene therapy aims to deliver a one-time treatment for severe hypertriglyceridemia and refractory hypercholesterolemia, conditions previously addressed in a 2025 clinical update and a publication in the New England Journal of Medicine.
CRISPR Therapeutics’ shares were trading at $57.08 at the close of U.S. markets on Monday, down $2.42, or 4.07%. Pre-market activity showed the stock at $56.97. Other firms have also weighed in on the company’s prospects: H.C. Wainwright maintained a $80 target and a Buy rating, while Morgan Stanley initiated coverage with a $60 target and an equal-weight rating. According to InvestingPro, 12 analysts have revised their earnings estimates upward for the upcoming period.
